



**To learn more about Rigel
Pharmaceuticals and TAVALISSE®
please contact us:**

Drew Dugger – Territory Business Manager, Jacksonville

Email: ddugger@rigel.com

Phone: (407) 488-6736

Deon Wolliston APRN MSN PhD – Senior Medical Science Liaison

Email: dwoolliston@rigel.com

Phone: (954) 895-2033

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information



**To learn more about Rigel
Pharmaceuticals and TAVALISSE®
please contact us:**

Holly Wayne – Territory Business Manager, Rochester

Email: hwayne@rigel.com

Phone: (608) 852-0739

Jimmy Gilbreth – Territory Business Manager, Rochester

Email: jgilbreth@rigel.com

Phone: (224) 563-7153

Aaron Sheppard, Ph.D – Senior Medical Science Liaison

Email: asheppard@rigel.com

Phone: (518) 937-3679

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information



**To learn more about Rigel
Pharmaceuticals and TAVALISSE®
please contact us:**

—

Margaret Hubble – Territory Business Manager, Scottsdale

Email: mhubble@rigel.com

Phone: (480) 263-3127

Ryan Flynn, PhD – Medical Science Associate Director

Email: rflynn@rigel.com

Phone: (817) 300-7251

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information